Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Lymphoproliferative Disorders × pertuzumab × 30 days × Clear all

Sponsor

Conditions

Breast Neoplasms 10 Neoplasms 4 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 HER2-positive Breast Cancer 2 Triple Negative Breast Neoplasms 1 Resectable HER2-positive Breast Cancer 1 Pathologic Complete Response 1 Neoplasm Metastasis 1 Malignant Solid Neoplasm 1 Hemangiosarcoma 1 HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients 1 HER2-positive Early Breast Cancer 1 Endometrial Neoplasms 1 Brain Neoplasms 1 Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

Cyclophosphamide 2 Bortezomib 2 trametinib 1 liposomal doxorubicin 1 isatuximab 1 fludarabine phosphate 1 fludarabine 1 dabrafenib 1 Zidovudine 1 Whole-Body Irradiation 1 Vincristine 1 Valganciclovir 1 Tacrolimus 1 Sirolimus 1 Rituximab 1 Prednisone 1 Peripheral Blood Stem Cell Transplantation 1 Patient Reported Outcome Measures 1 Nivolumab 1 Mycophenolic Acid 1 Mesna 1 Melphalan 1 Lenalidomide 1 Interferon-alpha 1 Granulocyte Colony-Stimulating Factor 1 Filgrastim 1 Etoposide 1 Doxorubicin 1 Dexamethasone 1 Busulfan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡